LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

McKesson Raises Quarterly Dividend by 15% to $0.71 Per Share

August 01, 2024 | Last Trade: US$727.74 5.04 -0.69

IRVING, Texas / Aug 01, 2024 / Business Wire / The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024.

“This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation,” said Brian Tyler, chief executive officer. “We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders.”

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page